Skin Diseases, Papulosquamous  >>  Ozespa (briakinumab)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ozespa (briakinumab) / AbbVie
NCT01260844: Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.

Withdrawn
1
12
US
briakinumab, ABT-874 Briakinumab
Abbott
Moderate to Severe Plaque Psoriasis
 
 

Download Options